针对癌症治疗的NEDD8激活酶:发展,临床试验,挑战和未来的研究方向
1Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Journal of hematology & oncology
|July 31, 2023
概括
对于生物过程和癌症而言,NEDDylation是至关重要的. NEDD8激活酶 (NAE) 抑制剂在癌症治疗的临床试验中显示出有前途,特别是血液瘤.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- NEDDylation是一种关键的翻译后修饰,调节生物过程.
- NEDD8激活酶 (NAE) 对于NEDDylation至关重要,也是抗癌药物开发的关键目标.
- 性NAE抑制剂正在癌症的临床试验中取得进展,特别是血液性恶性瘤.
研究的目的:
- 审查NEDDylation在癌症中的作用.
- 探索NAE的结构和功能.
- 讨论NAE抑制剂,它们的机制,以及癌症治疗的未来方向.
主要方法:
- 对NEDDylation路径的文献综述.
- 对NAE结构和催化机制的分析.
- 对NAE抑制剂的临床试验数据的检查.
- 讨论药物发现方法和挑战.
主要成果:
- NEDDylation通路与癌症的发展和进展密切相关.
- 阐明了NAE的独特结构和多步骤激活机制.
- 临床阶段的NAE抑制剂,包括共价类型,显示出治疗潜力.
- 介绍了发现NAE抑制剂的各种策略.
结论:
- NAE抑制剂代表了对各种癌症的有希望的治疗策略.
- 了解NAE的作用和抑制机制对于推进癌症治疗至关重要.
- 未来的研究应该集中在克服挑战和优化NAE向药物以提高疗效.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.8K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
